Department of Breast Surgery, Thyroid Surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No. 141, Tianjin Road, Huangshi, Hubei, China.
Dis Markers. 2019 Apr 4;2019:7593560. doi: 10.1155/2019/7593560. eCollection 2019.
A growing number of studies have explored the association between the pretreatment lymphocyte-to-monocyte ratio (LMR) and survival outcomes in various cancers. However, its prognostic significance on bladder cancer remains inconsistent. The aim of this meta-analysis was to evaluate the prognostic value of pretreatment LMR in bladder cancer.
The MEDLINE, EMBASE, Cochrane Library, and CNKI databases were comprehensively searched for relevant studies. A meta-analysis of overall survival (OS), recurrence-free survival (RFS), or cancer-specific survival (CSS) clinicopathological features was conducted.
Nine studies containing 5,638 cancer patients were analyzed in this meta-analysis. Patients with high LMR tended to have favourable OS (HR: 0.63, 95% CI: 0.50-0.80, < 0.001), RFS (HR: 0.59, 95% CI: 0.38-0.91, = 0.017), and CSS (HR: 0.76, 95% CI: 0.70-0.83, < 0.001). Moreover, low LMR was highly correlated with age (≥60), differentiation (low), T stage (III-IV), lymph node metastasis (yes), and concomitant Cis (yes).
Pretreatment LMR might be a useful predictor of survival outcomes in patients with bladder cancer.
越来越多的研究探讨了预处理淋巴细胞与单核细胞比值(LMR)与各种癌症生存结局之间的关系。然而,其在膀胱癌中的预后意义尚不一致。本荟萃分析旨在评估预处理 LMR 在膀胱癌中的预后价值。
全面检索 MEDLINE、EMBASE、Cochrane 图书馆和中国知网数据库中相关研究。对总生存(OS)、无复发生存(RFS)或癌症特异性生存(CSS)的临床病理特征进行荟萃分析。
本荟萃分析纳入了 9 项包含 5638 例癌症患者的研究。高 LMR 患者的 OS(HR:0.63,95%CI:0.50-0.80,<0.001)、RFS(HR:0.59,95%CI:0.38-0.91,=0.017)和 CSS(HR:0.76,95%CI:0.70-0.83,<0.001)均较好。此外,低 LMR 与年龄(≥60 岁)、分化(低)、T 分期(III-IV 期)、淋巴结转移(阳性)和同时合并 Cis(阳性)高度相关。
预处理 LMR 可能是膀胱癌患者生存结局的一个有用预测指标。